GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · Real-Time Price · USD
0.242
+0.026 (11.78%)
At close: Dec 24, 2024, 4:00 PM
0.240
-0.002 (-0.99%)
Pre-market: Dec 26, 2024, 5:17 AM EST
GlycoMimetics Employees
GlycoMimetics had 35 employees as of December 31, 2023. The number of employees decreased by 4 or -10.26% compared to the previous year.
Employees
35
Change (1Y)
-4
Growth (1Y)
-10.26%
Revenue / Employee
$286
Profits / Employee
-$1,135,287
Market Cap
15.61M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ProPhase Labs | 113 |
| bioAffinity Technologies | 75 |
| BioXcel Therapeutics | 74 |
| Unity Biotechnology | 19 |
| Traws Pharma | 18 |
| Innovative Eyewear | 11 |
| Minerva Neurosciences | 9 |
| Acurx Pharmaceuticals | 4 |
GLYC News
- 6 weeks ago - Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - PRNewsWire
- 7 weeks ago - GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - Business Wire
- 7 weeks ago - GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC - Business Wire
- 2 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - PRNewsWire
- 2 months ago - GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma - Business Wire
- 2 months ago - GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint - Business Wire
- 5 months ago - GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan - Business Wire
- 7 months ago - GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) - Business Wire